FDA Approves Donanemab: A Breakthrough in Early Alzheimer’s Treatment

Eli Lilly's once-monthly infusion shows significant promise in slowing cognitive decline and reducing amyloid plaques.

Donanemab, branded as Kisunla, targets amyloid plaques in the brain to slow Alzheimer's progression.
The drug demonstrated up to 39% reduction in disease progression and 40% less decline in daily functions.
Patients can potentially stop treatment after clearing amyloid plaques, reducing long-term costs.
Donanemab requires fewer infusions compared to other treatments, offering convenience for patients and caregivers.
Side effects include amyloid-related imaging abnormalities and infusion reactions, but benefits outweigh risks.